Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors

PURPOSE: To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of intravenous (IV) irinotecan when administered together in children with refractory solid tumors. To assess the effect of gefitinib on the ph...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Furman, Wayne L., Navid, Fariba, Daw, Najat C., McCarville, M. Beth, McGregor, Lisa M., Spunt, Sheri L., Rodriguez-Galindo, Carlos, Panetta, John C., Crews, Kristine R., Wu, Jianrong, Gajjar, Amar J., Houghton, Peter J., Santana, Victor M., Stewart, Clinton F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2009
Pynciau:
Original Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754908/
https://ncbi.nlm.nih.gov/pubmed/19687340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.6642
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg